Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

It features detailed molecular simulations of the ion channel in its native membrane environment across its open, closed, and inactivated forms, coupled with ensemble virtual screening considering conformational mobility in these states. Potential binding sites are explored within the pore, in the gating region, and at allosteric locations to encompass all potential mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8IWT1

UPID:
SCN4B_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8IWT1; E9PPT5; Q6PIG5

BACKGROUND:
Sodium channel subunit beta-4, identified by the unique identifier Q8IWT1, is pivotal in adjusting the kinetics of channel gating. It specifically induces negative shifts in the activation voltage dependence of alpha sodium channels and protects against venom-induced sodium channel inhibition. This subunit's function is essential for the proper operation of neuronal and cardiac sodium channels.

THERAPEUTIC SIGNIFICANCE:
The involvement of Sodium channel subunit beta-4 in Long QT syndrome 10 and familial atrial fibrillation 17 highlights its therapeutic potential. Targeting this protein could lead to innovative treatments for these disorders, which affect the heart's rhythm and can have severe consequences. Understanding the role of Sodium channel subunit beta-4 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.